The effect on lymphocyte subsets of decreasing/stopping tyrosine kinase inhibitor therapy in chronic myeloid leukaemia: data from the DESTINY trial

被引：9

作者：

Austin, Gemma M. ^{[1
]}

Knight, Katy ^{[2
]}

Bell, Joanne ^{[2
]}

Carter, Anthony ^{[2
]}

Heartin, Earnest ^{[3
]}

Watson, David ^{[4
]}

Foroni, Letizia ^{[5
]}

Christmas, Stephen E. ^{[6
]}

Polydoros, Fotios ^{[7
]}

Clark, Richard E. ^{[1
]}

机构：

[1] Univ Liverpool, Dept Mol & Clin Canc Med, Liverpool, Merseyside, England

[2] Royal Liverpool Univ Hosp, Dept Haematol, Liverpool, Merseyside, England

[3] Betsi Cadwaladr Univ Hlth Board, Ysbyty Glan Clwyd, Bodelwyddan, England

[4] Betsi Cadwaladr Univ Hlth Board, Wrexham Maelor Hosp, Wrexham, Wales

[5] Imperial Coll London, Hammersmith Hosp, Ctr Haematol, London, England

[6] Univ Liverpool, Dept Clin Infect Microbiol & Immunol, Liverpool, Merseyside, England

[7] Univ Liverpool, Liverpool Canc Trials Unit, Liverpool, Merseyside, England

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2019年 / 185卷 / 04期

关键词：

chronic myeloid leukaemia; treatment discontinuation; lymphocyte subsets; tyrosine kinase inhibitors; imatinib; TREATMENT-FREE REMISSION; IMATINIB DISCONTINUATION;

D O I：

10.1111/bjh.15629

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：791 / 793

页数：3

共 10 条

[1]

Clark R.E., 2018, EUR HAEM ASS ANN M S

[2] De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial [J].

Clark, Richard E. ;

Polydoros, Fotios ;

Apperley, Jane F. ;

Milojkovic, Dragana ;

Pocock, Christopher ;

Smith, Graeme ;

Byrne, Jenny L. ;

de lavallade, Hugues ;

O'Brien, Stephen G. ;

Coffey, Tony ;

Foroni, Letizia ;

Copland, Mhairi .

LANCET HAEMATOLOGY, 2017, 4 (07) :E310-E316

[3] Moving treatment-free remission into mainstream clinical practice in CML [J].

Hughes, Timothy P. ;

Ross, David M. .

BLOOD, 2016, 128 (01) :17-23

[4] Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia [J].

Ilander, M. ;

Olsson-Stromberg, U. ;

Schlums, H. ;

Guilhot, J. ;

Bruck, O. ;

Lahteenmaki, H. ;

Kasanen, T. ;

Koskenvesa, P. ;

Soderlund, S. ;

Hoglund, M. ;

Markevarn, B. ;

Sjalander, A. ;

Lotfi, K. ;

Dreimane, A. ;

Lubking, A. ;

Holm, E. ;

Bjoreman, M. ;

Lehmann, S. ;

Stenke, L. ;

Ohm, L. ;

Gedde-Dahl, T. ;

Majeed, W. ;

Ehrencrona, H. ;

Koskela, S. ;

Saussele, S. ;

Mahon, F-X ;

Porkka, K. ;

Hjorth-Hansen, H. ;

Bryceson, Y. T. ;

Richter, J. ;

Mustjoki, S. .

LEUKEMIA, 2017, 31 (05) :1108-1116

[5] Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia [J].

Luis Steegmann, Juan ;

Cervantes, Francisco ;

le Coutre, Philipp ;

Porkka, Kimmo ;

Saglio, Giuseppe .

LEUKEMIA & LYMPHOMA, 2012, 53 (12) :2351-2361

[6] Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study [J].

Rea, Delphine ;

Henry, Guylaine ;

Khaznadar, Zena ;

Etienne, Gabriel ;

Guilhot, Francois ;

Nicolini, Franck ;

Guilhot, Joelle ;

Rousselot, Philippe ;

Huguet, Francoise ;

Legros, Laurence ;

Gardembas, Martine ;

Dubruille, Viviane ;

Guerci-Bresler, Agnes ;

Charbonnier, Aude ;

Maloisel, Frederic ;

Ianotto, Jean-Christophe ;

Villemagne, Bruno ;

Mahon, Francois-Xavier ;

Moins-Teisserenc, Helene ;

Dulphy, Nicolas ;

Toubert, Antoine .

HAEMATOLOGICA, 2017, 102 (08) :1368-1377

[7] Musculoskeletal Pain in Patients With Chronic Myeloid Leukemia After Discontinuation of Imatinib: A Tyrosine Kinase Inhibitor Withdrawal Syndrome? [J].

Richter, Johan ;

Soderlund, Stina ;

Lubking, Anna ;

Dreimane, Arta ;

Lotfi, Kourosh ;

Markevarm, Berit ;

Sjalander, Anders ;

Saussele, Susanne ;

Olsson-Stromberg, Ulla ;

Stenke, Leif .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (25) :2821-2823

[8] The concept of treatment-free remission in chronic myeloid leukemia [J].

Saussele, S. ;

Richter, J. ;

Hochhaus, A. ;

Mahon, F-X .

LEUKEMIA, 2016, 30 (08) :1638-1647

[9] Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial [J].

Saussele, Susanne ;

Richter, Johan ;

Guilhot, Joelle ;

Gruber, Franz X. ;

Hjorth-Hansen, Henrik ;

Almeida, Antonio ;

Janssen, Jeroen J. W. M. ;

Mayer, Jiri ;

Koskenvesa, Perttu ;

Panayiotidis, Panayiotis ;

Olsson-Stromberg, Ulla ;

Martinez-Lopez, Joaquin ;

Rousselot, Philippe ;

Vestergaard, Hanne ;

Ehrencrona, Hans ;

Kairisto, Veli ;

Polakova, Katerina Machova ;

Mueller, Martin C. ;

Mustjoki, Satu ;

Berger, Marc G. ;

Fabarius, Alice ;

Hofmann, Wolf-Karsten ;

Hochhaus, Andreas ;

Pfirrmann, Markus ;

Mahon, Francois-Xavier .

LANCET ONCOLOGY, 2018, 19 (06) :747-757

[10] Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML [J].

Schuetz, C. ;

Inselmann, S. ;

Sausslele, S. ;

Dietz, C. T. ;

Mueller, M. C. ;

Eigendorff, E. ;

Brendel, C. A. ;

Metzelder, S. K. ;

Bruemmendorf, T. H. ;

Waller, C. ;

Dengler, J. ;

Goebeler, M. E. ;

Herbst, R. ;

Freunek, G. ;

Hanzel, S. ;

Illmer, T. ;

Wang, Y. ;

Lange, T. ;

Finkernagel, F. ;

Hehlmann, R. ;

Huber, M. ;

Neubauer, A. ;

Hochhaus, A. ;

Guilhot, J. ;

Mahon, F. Xavier ;

Pfirrmann, M. ;

Burchert, A. .

LEUKEMIA, 2017, 31 (04) :829-836

← 1 →